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Abstract
Lipid management remains the mainstay of cardiovascular disease prevention. 
Drugs that target cholesterol reduction, such as HMG-CoA reductase inhibitors 
(statins) and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, 
have shown significant mortality and morbidity benefit. Predominantly target-
ing low-density lipoprotein (LDL). These drugs have been indicated to reduce 
lipid composition and plaque proliferation. Total plaque burden and composition 
can now be assessed with noninvasive advanced cardiac imaging modalities. This 
chapter will address the components of atherosclerotic plaque as identified with 
coronary computed tomography angiography (CCTA) and review in detail the 
changes in plaque characteristics that may be responsible for reduction in cardiac 
events. These changes in plaque composition may help guide future management of 
cardiovascular disease, serving as an imaging biomarker for better risk stratifica-
tion. Readers will gain a deeper understanding of plaque morphology with direct 
clinical applicability as well as an understanding of how noninvasive imaging can be 
utilized to assess plaque composition.
Keywords: coronary computed tomography angiography (CCTA), statin, PCSK9, 
low density lipoprotein (LDL), atherosclerotic plaque
1. Introduction
Cardiovascular disease (CVD) has remained the leading cause of death in the 
United States in 2018 [1]. Atherosclerosis is the leading factor in causing cardiovas-
cular death. The main factors that drive atherosclerosis are LDL cholesterol, hyper-
tension, diabetes, and smoking [2]. Currently the United Stated Preventive Services 
Task Force recommends screening everyone who are at risk for coronary artery 
disease, all men over age 35 and all women over age 45. For risk stratification a ten 
year atherosclerotic risk score can be calculated to help decide if treatment should 
be started [3]. Treatment options can be aided by cardiac imaging. Cardiac imag-
ing is mainly performed via intravascular ultrasound (IVUS), optical coherence 
tomography (OCT), and coronary computed tomography angiography (CCTA). 
Dyslipidemia
2
This development has made plaque characterization possible. Categories of plaque 
are placed into 4 broad categories: low-attenuating, fibrofatty, fibrocalcified, and 
densely calcified plaque [4].
2. Pathophysiology of atherosclerosis
The coronary arteries are composed of three layers: tunica intima, tunica media, 
and tunica adventitia. The tunica intima is the innermost lining inside these vessels, 
which is further composed of three layers of the endothelium. Simple squamous 
cells make up the innermost layer, which functions as a barrier that allows blood 
to flow smoothly. Any break in any part of the endothelial lining exposes blood to 
the subendothelial layer, starting the clotting mechanism. The tunica media is the 
middle layer of the vessels, composed of layers of smooth muscle cells. The tunica 
adventitia is the outer connective tissue layer supporting the vessel itself formed 
of loose connective tissue, vessels, and nerves [1]. When the initial fatty streaks or 
plaque precursors grow, it is usually outward, meaning there is not an initial direct 
effect on the blood flow or size of the lumen [5]. Lesions progress when the intima’s 
smooth muscle cells begin to divide and secrete extracellular matrix molecules, such 
as collagen [6]. Other smooth muscle cells will penetrate the intima from the media, 
where they will join the other muscle cells in forming a fibrous cap overlying the 
lipid core. When there is a persistence of risk factors such as high LDL levels, the 
lipid core continues to grow in this manner.
The major lipoprotein classes include chylomicrons, very low-density lipopro-
teins (VLDL), intermediate-density lipoproteins, low-density lipoproteins (LDL), 
and high-density lipoproteins (HDL). Larger in size and more triglyceride-rich 
lipoproteins are the less dense. Protein molecules, known as apolipoproteins (apo) 
on these particles’ surface, guide the lipoproteins’ interaction with tissues, cells, and 
different organs. LDL receptors bind to apo-B, the predominant apoprotein in LDL, 
and apo-E found on VLDL and some HDL particles. This receptor-mediated uptake 
delivers circulating cholesterol to the liver and other tissues. Apo-B may contribute 
to LDL’s atherogenicity by promoting Apo-B particle entrapment within the arterial 
wall. Apo A-I, the predominant apoprotein in HDL, aids antiatherogenic efflux of 
cholesterol from peripheral tissues [6].
The different type of plaque morphology includes foam cell-rich matrix 
(obtained from fatty streaks), collagen-rich matrix (from sclerotic plaques), 
collagen-poor matrix without cholesterol crystals (from fibrolipid plaques), 
atheromatous core with abundant cholesterol crystals (from atheromatous 
plaques), and segments of normal intima derived from human aortas at necropsy. 
Atheromatous cores are associated with the most significant platelet deposition 
and largest thrombus formation than other components of atherosclerotic lesions. 
Therefore, we are led to believe that atherosclerotic plaques with larger atheroma-
tous cores are more prone to cause acute coronary events because of their greater 
thrombogenicity after rupture [7].
Studies have also shown that aggressively lowering LDL cholesterol alters the 
composition of coronary atheromas. Lowering LDL cholesterol decreases the size 
of the lipid core, stabilizing the plaque by decreasing the lipid core and increasing 
the ratio of fibrous tissue to atheroma. This stabilizes the plaque by increasing the 
calcification of the plaque, reducing likelihood of plaque rupture [6]. There is an 
increase in fibrous tissue and calcified tissue within the atheroma replacing the lipid 
core. Therefore, calcification increases with aggressive lipid-lowering therapies like 
statins.
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Noninvasive imaging modalities such optical coherence tomography (OCT), 
intravascular ultrasound (IVUS), and coronary computed tomography angiography 
(CCTA) have the ability to characterize plaque based on the above pathophysiology 
and define high risk features that in turn increase risk of cardiovascular events [8].
3. Plaque characterization by noninvasive imaging
Coronary artery calcium scoring and coronary artery calcification assessment 
are among the most emerging noninvasive coronary artery imaging applications. 
Initially, calcifications on chest radiography and ex vivo histology were used to 
discuss the relationship between coronary calcification and obstructive coronary 
artery diseases. The coronary artery calcium (CAC) scan consists of a non-contrast, 
electrocardiogram gated computed tomography of the heart. It is obtained dur-
ing a short period of held inspiration. Once the image is obtained, the arterial 
calcium is defined using Hounsfield units. A density of greater than 130 Hounsfield 
units across an area of at least 1 mm is considered significant. Atherosclerotic 
calcification is reported either by volume or mass in Agatston units (AU), a semi-
quantitative measure that further incorporates aspects of calcium density and 
distribution [9].
Progression of coronary calcium scores have a direct impact on clinical coro-
nary events. One of the largest cohorts, the Multi-Ethnic Study of Atherosclerosis 
(MESA), followed over 5,600 patients. Participants received initial CAC scans 
and were followed for a median duration of 7.6 years, and then received follow up 
CAC. The change in calcium score was measured between initial and follow up was 
correlated with coronary artery events. Endpoints included myocardial infarction, 
angina followed by revascularization, resuscitated cardiac arrest, and cardiac death. 
Patients with non-zero CAC score at baseline were more likely to be older, male, 
diabetic, previous smoker and be on lipid lowering medication or hypertensive 
medication. Eighty-four percent of patients with a zero CAC score at baseline 
remained at zero on follow up. Patients with calcium score increases greater than 
100 had a two to three-fold greater risk for the cardiac endpoints. Patients with 
15–29% annual increase in CAC had an increased risk (hazard ratio: 1.6) for cardiac 
events compared to those with less than five percent progression annually. The 
study concluded that CAC scores correlate with clinical events including MI and 
cardiac death [10].
Computed tomography can characterize plaque morphology based upon 
Hounsfield Units, identifying high risk plaque. Plaque morphology on CCTA is 
characterized as low-attenuating plaque, fibrofatty, fibrocalcified and densely calci-
fied. High risk or vulnerable plaque features include low-attenuating, spotty calci-
fication and positive remodeling. Compared with intravascular ultrasound,, CCTA 
has shown high sensitivity and specificity in evaluating plaque morphology [4].
A large study published in the Journal of American College of Cardiology by 
Motoyama et al. established CCTA characterization of plaque morphology and 
the clinical implications. The study stratified patients into different morphologi-
cal groups. Low attenuated plaque was defined as less than 30 Hounsfield Units. 
This was correlated with previous studies using intravascular ultrasound showing 
a sensitivity of 91% and specificity of 100%. %. Intermediate attenuated plaque 
was defined 30 HU to 150 HU and calcified plaque was defined as greater than 150 
HU. Remodeling was the other factor in this study (positive, negative, or none). 
Coronary artery positive remodeling was defined as when the size of the lumen 
is increased by 10% more in the region of the plaque than in a reference segment 
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proximal to the plaque. This large study showed that when a subject has both posi-
tive remodeling and low attenuated plaque they are at high risk for having an acute 
coronary syndrome in the next two years. Twenty two percent of subjects with 
both low attenuated plaque and positive remodeling had acute coronary syndrome 
within the next two years compared to less than one half of one percent of the 
subjects with neither positive remodeling nor low attenuated plaque [11].
Several trials have demonstrated that use of statin therapy has shown benefit 
in primary prevention of coronary artery disease and secondary prevention of 
coronary artery disease. Statins have become the standard of care in coronary artery 
disease and are in all major anti lipid and coronary artery disease guidelines. Statins 
offer several benefits. Directly, they reduce hepatic cholesterol synthesis but several 
pleiotropic effects have been defined, including reduction in inflammation, cho-
lesterol egress from the vasculature and plaque stabilization as described. There are 
many different areas of research being performed on various potential beneficial 
effects of statin therapy including beneficial effect on vascular tone by the upregu-
lation of nitric oxide, reducing platelet aggregation and having antithrombotic 
properties, and anti-inflammatory properties including reduction in oxidative 
stress [4].
4.  Changes in atherosclerotic plaque composition with lipid lowering 
therapies
4.1 Statins
Cardiovascular disease (CVD) has remained the leading cause of death in the 
United States in 2018 [9]. One of the main targets in the biosynthesis of choles-
terol is inhibition of 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMG 
CoA). Reduction in low density lipoprotein (LDL) cholesterol and then therefore 
reduction in morbidity and mortality has been achieved in several trials includ-
ing Scandinavian Simvastatin Survival Study and West of Scotland Prevention 
Study [4].
Computed tomography can characterize plaque morphology based upon 
Hounsfield Units. This can identify at risk plaque. Plaque morphology on CCTA is 
identified as low-attenuating, fibrofatty, fibrocalcified, and densely calcified. At 
risk or vulnerable plaque is low-attenuating plaque. Intravascular ultrasound is the 
gold standard in characterizing plaque, however CCTA has shown high sensitivity 
and specificity in evaluating plaque morphology [10].
A large study published in the Journal of American College of Cardiology by 
Motoyama et al. established CCTA characterization of plaque morphology and 
the clinical implications. The study stratified patients into different morphologi-
cal groups. Low attenuated plaque was defined as less than 30 Hounsfield Units. 
This was correlated with previous studies using intravascular ultrasound showing 
a sensitivity of 91% and specificity of 100%. %. Intermediate attenuated plaque 
was defined 30 HU to 150 HU and calcified plaque was defined as greater than 150 
HU. Remodeling was the other factor in this study (positive, negative, or none). 
Coronary artery positive remodeling was defined as when the size of the lumen 
is increased by 10% more in the region of the plaque than in a reference segment 
proximal to the plaque. Therefore, a subject could have both low attenuated plaque 
and positive remodeling, either low attenuated plaque or positive remodeling, or 
neither low attenuated plaque nor positive remodeling. This large study showed that 
when a subject has both positive remodeling and low attenuated plaque they are 
at high risk for having an acute coronary syndrome in the next two years. Twenty 
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two percent of subjects with both low attenuated plaque and positive remodeling 
had acute coronary syndrome within the next two years compared to less than one 
half of one percent of the subjects with neither positive remodeling nor low attenu-
ated plaque Several trials have demonstrated that use of statin therapy, HMG-CoA 
reductase inhibition, has shown benefit in primary prevention of coronary artery 
disease and secondary prevention of coronary artery disease. Statins have become 
the standard of care in coronary artery disease and are in all major anti lipid and 
coronary artery disease guidelines. They also have mortality benefits as well. Statins 
work in the pathway of cholesterol synthesis. This occurs in the hepatocytes. This 
results in upregulation of hepatic LDL receptors and reduces serum LDL. This 
causes reduction in LDL deposition on atherosclerotic plaque on coronary arteries 
and other arteries for that matter. Statins also have reduction in the inflamma-
tory cascade as well. Overall there is stabilization of atherosclerotic plaque due to 
statin therapy. There are several trials including Rosuvastatin to Prevent Vascular 
Events in Men and Women With Elevated C-Reactive Protein (JUPITER), Effects 
of Atorvastatin on Early Recurrent Ischemic Events in Acute Coronary Syndromes 
(MIRACL), and Heart Outcomes Prevention Evaluation (HOPE-3) that all show 
reduction in C-Reactive Protein (CRP). This also could aid in reduction of coronary 
events but is still controversial at this point. There are many different areas of 
research being performed on various potential beneficial effects of statin therapy 
including beneficial effect on vascular tone by the upregulation of nitric oxide, 
reducing platelet aggregation and having antithrombotic properties, and anti-
inflammatory properties including reduction in oxidative stress [10] Atherosclerotic 
plaque can regress. Plaque regression occurs when there is removal of lipids and 
necrotic material from the plaques, endothelial repair occurs, and smooth muscle 
proliferation stops. This can occur by several different mechanisms: high density 
lipoprotein cholesterol, destruction of foam cells and macrophages, and restoration 
of endothelium. Statin therapy has been studied in the process of atherosclerotic 
plaque reduction. Meta-analysis of eight trials comparing statin with placebo 
showed that in 919 patients with 461 patients in the statin arm and 458 patients 
in the placebo group that there was a statistically significant mean difference in 
coronary atheroma volume between the two groups. -3.573 (95% CI -4.46 to −2.68; 
P < 0.01). Plaque characterization was similar in both groups. Intravascular ultra-
sound was used in the studies [12].
Coronary CTA has allowed physicians to directly visualize atherosclerotic plaque 
characterization and volume. This allows identification of features of vulnerable 
plaque including positive remodeling and low attenuating plaque, altering clinical 
management [4]. One early study on the effects of statin therapy via coronary CTA 
by Zeb et al. evaluated one hundred patients who underwent coronary CTA without 
known history of coronary artery disease. Patients underwent plaque characteriza-
tion as low attenuation plaque (LAP as less than 30 Hounsfield units), non-calcified 
plaque (NCP) and calcified plaque and volumetric quantification among a statin 
versus non-statin arm. This was a retrospective observational study in attempts 
to evaluate the plaque volume and characteristics over time. At mean follow up 
of 406 days the total plaque volume was reduced in the statin arm compared to 
the non-statin arm (−33.3 mm3 +/− 90.5 vs. 31 mm3 +/− 84.5, p = 0.0006). Non 
calcified plaque volume was significantly reduced in the statin therapy arm as well 
(−47.7 mm3 +/− 71.9 vs. 13.8 mm3 +/− 76.6, p < 0.001). Low attenuated plaque vol-
ume was shown to have significantly reduced progression (−12.2 mm3 +/− 19.2 vs. 
5.9 mm3 +/− 23.1, p < 0.0001). There was a non-significant trend toward increased 
production of calcified plaque volume. Mean plaque volume difference was statisti-
cally significant for both low attenuated plaque and non-calcified plaque (−18.1, 
95% Cl: −26.4, −9.8 for LAP; −101.7, 95% Cl: −162.1, −41.4 for NCP; p < 0.001). 
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The authors concluded that statin therapy lowers the progression of LAP and NCP 
plaque in comparison with non-statin therapy [13].
Another landmark trial using CT derived plaque characterization was the 
Paradigm study (Progression of Atherosclerotic Plaque Determined by Computed 
Tomographic Angiography. This multinational, observational prospective study 
evaluated serial coronary CTA’s at a greater than two-year interval. With 654 
enrolled patients, the majority of patients were on statin therapy (408 vs. 246). 
All patients had baseline coronary CTA’s, followed for greater than two years, and 
then had subsequent coronary CTA. In the statin arm initial low density lipopro-
tein (LDL) cholesterol was on average 114 and reduced to 94.5 at follow up. The 
non-statin arm had an initial average LDL of 111 and follow up LDL of 104. The 
plaque was characterized into calcified and non-calcified plaque including: fibrous, 
fibro-fatty, and lipid rich. The authors demonstrated that an increase in coronary 
artery calcium score was associated with the increase in plaque volume in both 
the statin and non-statin groups. In the non-statin arm coronary artery calcium 
score was associated with increase in calcified and non- calcified plaque volume 
increase [B (95% CI): 1.579 (1.150–2.009) and 0.369 (0.123–0.614), respectively, all 
P < 0.05). In the statin arm there was a statistically significant increase in coronary 
artery calcium score associated with increased calcified plaque volume [B (95% CI): 
0.756 (0.552–0.961), P < 0.001]. Non calcified plaque volume decreased [B (95% 
CI): −0.194 (−0.364 to −0.023), P = 0.026). Fibrous plaque volume also decreased 
as well [B (95% CI): −0.304 (−0.535 to −0.073), P = 0.010]. The fibro fatty and 
lipid rich plaque volume also decreased but was not statistically significant. In 
the non-statin arm, the increase in coronary calcium score reflects the increased 
atherosclerotic burden including calcified and non-calcified plaque. The statin 
arm increase in coronary calcium score only is correlated with calcified plaque. 
Therefore, in the statin arm, while the calcified plaque increased the fibrous and 
overall, non-calcified plaque decreased. With statin therapy, the ratio of plaque 
composition shifts to more stable, lower risk morphology, specifically calcified and 
fibrocalcified types [14].
Another variable of coronary atherosclerosis is the fibrous cap. A thin fibrous 
cap can also be a sign of vulnerability, increasing risk for plaque rupture and 
presenting with acute coronary syndrome [15]. The EASY-FIT study (Effect Of 
Atorvastatin Therapy On Fibrous Cap Thickness In Coronary Atherosclerotic 
Plaque As Assessed By Optical Coherence Tomography) assessed the differences 
between Atorvastatin 5 mg and Atorvastatin 20 mg on the fibrous cap using optical 
coherence tomography. The EASY-FIT study enrolled 70 patients with unstable 
angina pectoris who had untreated hyperlipidemia. These patients were previously 
treated with successful percutaneous coronary intervention (PCI). The OCT that 
was performed looked at a nonculprit lesion in the coronary artery. Patients were 
placed in either an Atorvastatin 20 mg/day arm or a 5 mg/day arm with OCT at 
baseline and at 12-month follow-up. Thin-cap fibroatheroma was defined as plaque 
having minimal fibrous cap thickness of <65 micrometers and thick cap was defined 
as fibrous cap thickness > 65 micrometers. The fibrous cap thickness increased sig-
nificantly in both groups. In the Atorvastatin 20 mg/day vs. 5 mg/day the increase 
was (69% [IQR: 25% - 104%] vs. 17% [IQR: −1% to 34%] p < 0.001. The minimal 
lumen area did not change at follow up for either group. There was a negative cor-
relation between the fibrous cap thickness and the serum LDL but no correlation 
between total serum cholesterol, triglycerides, or glycosylated hemoglobin. This 
study suggests that high to moderate intensity statin might be superior in providing 
benefit in plaque stabilization compared to low intensity Atorvastatin in secondary 
prevention in the setting of unstable angina [16].
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5. Effects of EPA on atherosclerotic plaque via CCTA
There is limited evidence about the effects of eicosapentaenoic acid (EPA) on 
atherosclerotic plaque. The mechanism of action of these omega 3 fatty acids occurs 
several ways: reducing inflammation, plaque volume, membrane stabilization as 
well as triglyceride reduction. There is some evidence that EPA might have an effect 
on atherosclerotic plaque volume and characterization. The Evaporate trial (Effect 
of icosapent ethyl on progression of coronary atherosclerosis) was a multicenter, 
randomized, double-blinded, placebo-controlled trial with intention to treat analy-
sis which evaluated patients with known coronary artery disease and hypertriglyc-
eridemia already on statin therapy. Patients in the EPA arm were given four grams 
of EPA daily and their plaque progression was measured by CCTA. They had CCTA 
scans at baseline, 9 months and 18 months. The primary end point was the change 
in low attenuated plaque volume seen on CCTA. Low attenuated plaque volume was 
significantly reduced in the EPA arm of the study at 18 month follow up vs. placebo 
(−0.3 +/− 1.5 vs. 0.9 +/− 1.7 mm3, P = 0.006). Other parameters EPA arm vs. 
placebo arm respectively: total plaque (−9% vs. 11% P = 0.002), total non-calcified 
plaque (−19% vs. 9%, P = 0.0005), fibrofatty (−34% vs. 32%, P = 0.0002), fibrous 
(−20% vs. 1%, P = 0.003), and calcified plaque (−1% vs. 15%, P = 0.053). Dense 
calcium did not show significant difference between the two groups. Interestingly 
there was no significant difference in total cholesterol, LDL, HDL or triglycerides 
compared to baseline. The study concluded that EPA was associated with plaque 
regression, specifically the low attenuation, higher risk plaque, compared to statin 
therapy alone [17].
Of critical importance is whether the change in plaque composition with addi-
tion of EPA translates into a reduction in cardiovascular events. The REDUCE-IT 
trial (Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial) 
is a randomized, double blinded, placebo controlled trial comparing EPA (4 g 
total) to placebo. Over eight thousand patients were enrolled and followed for an 
average of 5 years. In this trial enrollment only occurred for age 45 and older with 
cardiovascular disease or were age 50 or older with diabetes and at least one other 
cardiovascular risk factor. Requirements also included: fasting triglyceride level of 
150–499 mg/dL, LDL cholesterol level of 41–100 mg/dL, and on the same statin 
dose for at least four weeks. The primary end point was composite of cardiovascular 
death, nonfatal myocardial infarction, nonfatal stroke, coronary revasculariza-
tion, or unstable angina in time to event analysis. Secondary end points included: 
key secondary efficacy end point, composite of cardiovascular death or nonfatal 
MI, fatal or nonfatal MI, emergency or urgent revascularization, cardiovascular 
death, hospitalization for unstable angina, fatal or nonfatal stroke, death from any 
cause, non-fatal MI or non-fatal stroke. The primary end-point occurred in 17.2% 
of patients in the icosapent ethyl arm compared to 22% in the placebo arm (hazard 
ratio, 0.75; 95% confidence interval, 0.68 to 0.83; P < 0.001), absolute between 
group difference of 4.8% (95% CI, 3.1 to 6.5). The number needed to treat in order 
to avoid one primary end point was 21 over a 5 year follow up. Key secondary 
end points occurred in 11.2% of patients in the icosapent ethyl arm compared to 
14.8% in the placebo arm (hazard ratio, 0.74, 95% CI, 0.65 to 0.83; P < 0.001) with 
absolute between group difference of 3.6% (95% CI, 2.1 to 5.0). The number needed 
to treat to avoid one key secondary end point was 28 (95% CI, 20 to 47) in a 5 year 
follow up. For individual primary and secondary end points icosapent ethyl arm 
vs. placebo arm respectably: rate of cardiovascular death (4.3% vs. 5.2%; 0.80; 95% 
CI, 0.66 to 0.98; P = 0.03), death from any cause (6.7% vs. 7.6%, 0.87; 95% CI, 0.74 
to 1.02). All primary and secondary end points significantly statistically favored 
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the icosapent ethyl arm compared to placebo except for death from any cause. The 
study authors concluded that in patients 45 years and older with hypertriglyceride-
mia receiving statin therapy, cardiovascular risk including cardiovascular death was 
lowered with icosapent ethyl therapy than with placebo [18].
6. Effects of PCSK9 inhibitors on atherosclerotic plaque via CCTA
Statin therapy has been the standard for the reduction of LDL cholesterol for 
fifty plus years. However, there is still cardiovascular risk even after high dose statin 
therapy. To reduce this risk more medications have been developed and imple-
mented. One class is the Proprotein convertase subtilisin/kexin type 9 (PCSK9) 
inhibitors. Studies have shown that PCSK9 inhibitors reduce LDL cholesterol and 
reduce clinical events. An initial study looking at plaque via intravascular ultra-
sound called the Global Assessment of Plaque Regression with a PCSK9 Antibody as 
Measured by Intravascular Ultrasound (GLAGOV) showed that there was decrease 
in percent atheroma volume after 76 weeks with PCSK9 therapy in addition to statin 
therapy. The primary end point of percent atheroma volume did not decrease in the 
placebo group but did decrease in the evolucumab group (0.05% vs. 0.95%). The 
between group difference is −1.0% (95% CI, −1.8% to −0.64%) P < 0.001 [19].
In this next trial coronary calcium score was mainly used in combination with 
coronary CTA to evaluate plaque production in three groups: statin, statin plus 
PCSK9 inhibitor, and no therapy. This study was a retrospective study to evaluate if 
PCSK9 inhibitors could reduce the plaque burden that is already present in patients. 
This was performed by evaluating the association between PCSK9 inhibitor therapy 
and coronary calcium score via CCTA. Baseline characteristics of the 120 patients 
that were retrospectively enrolled in this study showed that 53% of patients had 
calcium score of zero, 47% of patients had coronary calcium score of greater than 
zero. Twelve and a half percent had severe coronary artery calcification with scores 
>400 AU’s. A correlation was observed between coronary calcium score and lipid 
lowering therapy (P < 0.0001) without correlation between any other traditional 
risk factor for coronary artery disease including hemoglobin A1c levels, blood pres-
sure, and lipid levels. Scores increased with age (P = 0.048) particularly age greater 
than sixty years old. Coronary artery calcium score was higher in the statin and 
statin plus PCSK9 group mainly because they had higher diagnosed coronary artery 
disease and therefore required lipid lowering therapy. Calcium score was measured 
annually. The progression in the statin monotherapy group was 29.7% and 14.3% 
in the PCSK9 inhibitor group (P < 0.01). There is a clear association between the 
lower plaque production via coronary calcium score due to PCSK9 therapy. This 
is a low powered study with a low patient enrollment. There were several limita-
tions including being an open label design, short study duration, all participants 
were Japanese, and difference in statin dose. More studies need to be performed to 
include a longer term, double blinded, prospective study. However, in this initial 
study coronary artery calcium score was reduced from 29.7% in the statin group and 
14.3% in the statin plus PCSK9 group. Plaque progression might be prevented by 
additional therapy with PCSK9 inhibitor therapy [20]. This study can set the stage 
for future studies using coronary CTA to follow the atherosclerotic plaque with 
PCSK9 inhibitor therapy. Characteristics of atherosclerotic plaque should also be 
reviewed in future studies.
Patients with certain comorbidities in addition to coronary artery disease 
are at higher risk for further acute coronary syndrome events. One comorbidity 
being diabetes mellitus. The American Diabetes Association is also interested in 
reducing cardiovascular risk for their subset of patients. In the 457-P: One-Year 
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Administration of Anti-PCSK9 Antibody Is Enough to Stabilize Vulnerable 
Coronary Plaques in Diabetic Patients, which Are Resistant to Intensive Statin 
Therapy trial they attempted to review the efficacy of PCSK9 therapy. As previ-
ously described low attenuating plaque is categorized as vulnerable plaque and 
is associated with increased risk of acute coronary syndrome. In this study 142 
patients with type two diabetes mellitus, asymptomatic coronary artery disease 
with vulnerable coronary plaques, on intensive statin therapy for two years were 
evaluated by coronary CTA to evaluate the plaque. PCSK9 inhibitors were given for 
a one-year duration. There was a 74% decrease in LDL cholesterol. Importantly an 
improvement of vulnerable plaque was seen. This was measured by Housfield Units 
(HU). As explained previously vulnerable plaque or low attenuating plaque have a 
Housfield Unit of less than 50. There was a rise in plaque HU (43.2 +/− 12.0 HU at 
baseline to 128.5 +/− 52.3 HU, p < 0.0001 after one year of PCSK9 therapy). This 
infers stabilization of vulnerable plaque in the setting of diabetic patients on inten-
sive statin therapy with vulnerable plaque seen on CCTA. The conclusion was drawn 
that a one- year administration of PCSK9 inhibitor therapy produced significant 
stabilization of vulnerable plaque in patients with asymptomatic coronary artery 
disease who are resistant to intensive statin therapy [21].
Overall there is very minimal data in this category. This is an area for future 
studies. Many studies are currently being performed in this area and will continue 
to explore this area of research. Plaque progression, plaque volume, plaque charac-
terization can all be assessed via coronary CTA. This gives cardiologists advantages 
in treatment options and more informed discussion with patients. Further research 
in this area is needed.
7. Future directions
There are several areas for future research. One is epicardial fat and pericoro-
nary fat. For example, in the trial Epicardial adipose tissue and pericoronary 
fat thickness measured with 64-mutidetector computed tomography: potential 
predictors of the severity of coronary artery disease they looked at epicardial and 
pericoronary fat to see if there was association between the amount of fat thickness 
to the severity of coronary artery disease. This showed that there was in increase in 
fat thickness in patients with obstructive coronary artery disease [22]. This research 
is in the beginning stages and much further research can be done.
A new software has been developed called Cleerly software that uses artificial 
intelligence to quantify coronary artery stenosis and plaque composition at the 
vessel and lesion level in order to track it over time. This is another clinical tool that 
is taking an invasive procedure like a coronary artery catheterization and making 
it noninvasive and easily accessible to patient and physician on an online platform. 
This helps clinicians determine the best treatment approach for each individual-
ized patient. This is a very small part of a bigger overarching vision of precision 
medicine.
8. Conclusion
Atherosclerosis is an evolving field with an explosion of data coming recently of 
various subsets which include different imaging modalities, plaque characteriza-
tion, and treatment options. This has allowed the medical field to delve into the 
pathophysiology of atherosclerotic plaque formation, how to properly image this 
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mortality. The coronary CTA has allowed us to look at the morphology of athero-
sclerotic plaque and to be able to track the plaques over time on various treatments 
including statin therapy which is the gold standard, icosapent ethyl therapy, and 
the newest treatment of PCSK9 inhibitors. Many trials as discussed above have 
shown the effects of various medications on atherosclerotic plaque over time and 
how it correlates to the morphology of the plaque and how this correlates clinically. 
The morphology change from a high risk plaque to a low risk plaque with a higher 
calcification is one of the key discoveries that coronary CTA allowed us to see. The 
non- invasive approach of this modality is clearly the future of following atheroscle-
rosis in patients on lipid lowering therapy. Future research needs to be performed 
on the effects PCSK9 inhibitors on atherosclerotic plaque via coronary CTA as 
well as continued trials connecting clinical events and mortality to lipid lowering 
therapy via coronary CTA.
© 2021 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
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